Swedish float for Biovitrum
Biovitrum, the Swedish biotechnology group that last year acquired Cambridge Biotechnology Ltd, is aiming to raise £363.5m from a float on the Stockholm Stock Exchange.Biovitrum is one of the largest biopharma companies in Europe.
With operations in Sweden and in the UK, Biovitrum conducts research and develops pharmaceuticals for unmet medical needs both for common diseases and conditions that affect smaller patient populations. It
intends to use the proceeds to fund international growth.